APX701 / Pyxis Oncology - LARVOL DELTA

[VIRTUAL] Targeting SIRPα with APX701, a Novel Myeloid Checkpoint Inhibitor (AACR 2021) - "APX701 reverses SIRPα-mediated suppression of macrophage phagocytosis, resulting in potent destruction of a variety of tumor cells both as a single agent and in combination with anti-TAA (tumor associated antigen) antibodies including cetuximab, rituximab, and trastuzumab. Together, these data demonstrate the unique binding profile of APX701 and its ability to potently reactivate myeloid cell-mediated anti-tumor immunity. Our data support the development of APX701, a promising myeloid checkpoint inhibitor, for the treatment of cancer."

Checkpoint inhibition • Late-breaking abstract • Oncology

Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021 (PRNewswire) - "Apexigen...announced two upcoming poster presentations accepted as late breaking abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2021, to be held virtually April 10-15, 2021...The posters will be available on the e-poster website from at 8:30 am EDT on April 10, 2021, through June 21, 2021."

Preclinical • Oncology

Apexigen Announces Presentations Of Preclinical Data For Its TNFR2 Antagonist (APX601) And SIRPα Antagonist (APX701) Programs At The AACR Annual Meeting 2021 (PRNewswire) - “Apexigen, Inc…announced two upcoming poster presentations accepted as late breaking abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2021, to be held virtually April 10-15, 2021. Details are as follows: Title of Presentation: APX601, a Potent TNFR2 Antagonist as a Novel and Promising Approach to Reverse Tumor Immune Suppression; Title of Presentation: Targeting SIRPα with APX701, a Novel Myeloid Checkpoint Inhibitor (Abstract ID LB177).”

Preclinical • Oncology